Exicure acquires GPCR Therapeutics USA and signs license/collaboration agreement

EXICURE, INC.

Acquired all outstanding equity of GPCR Therapeutics USA from GPCR Therapeutics Inc.; deal closed concurrently with execution.
Entered License and Collaboration Agreement to develop and commercialize GPCR's technologies and patents.
Must make milestone payments tied to clinical trial, regulatory, and sales milestones; royalty of at least 10% of net sales.
Corrected press release filed as an amendment to the January 22, 2025 8-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.